Compare Microchip Technology Inc. (MCHP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Microchip Technology Inc. trades at $82.22 (market cap $44.20B), while Vertex Pharmaceuticals Incorporated trades at $528.02 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3× Microchip Technology Inc.'s market cap, and Microchip Technology Inc. pays a 2.24% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MCHP | VRTX | |
|---|---|---|
Market Cap | $44.20B | $132.79B |
Sector | Technology | Health |
52-Week High | $102.97 | $529.65 |
52-Week Low | $49.02 | $376.62 |
Enterprise Value | $49.32B | $126.92B |
Dividend Yield | 2.24% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
